The emergence and spread of carbapenem-resistant Gram-negative pathogens is a global public health problem. The acquisition of metallo-b-lactamases (MBLs) such as NDM-1 is a principle contributor to the emergence of carbapenemresistant Gram-negative pathogens that threatens the use of penicillin, cephalosporin and carbapenem antibiotics to treat infections. To date, a clinical inhibitor of MBLs that could reverse resistance and re-sensitize resistant Gram-negative pathogens to carbapenems has not been found. Here we have identified a fungal natural product, aspergillomarasmine A (AMA), that is a rapid and potent inhibitor of the NDM-1 enzyme and another clinically relevant MBL, VIM-2. AMA also fully restored the activity of meropenem against Enterobacteriaceae, Acinetobacter spp. and Pseudomonas spp. possessing either VIM or NDM-type alleles. In mice infected with NDM-1-expressing Klebsiella pneumoniae, AMA efficiently restored meropenem activity, demonstrating that a combination of AMA and a carbapenem antibiotic has therapeutic potential to address the clinical challenge of MBL-positive carbapenem-resistant Gram-negative pathogens.
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The b-lactams (penicillins, cephalosporins, carbapenems and monobactams) are one of the most important and frequently used classes of antibiotics in medicine and are essential in the treatment of serious Gram-negative infections. Since the clinical introduction of penicillins and cephalosporins over 60 years ago, the emergence of b-lactamases, enzymes that hydrolyse the b-lactam ring that is essential for the cellkilling activity of the antibiotics, has been an ongoing clinical problem 1 . Antibiotic resistance has intensified medicinal chemistry efforts to broaden antibacterial spectrum while shielding the core b-lactam scaffold from b-lactamase-catalysed hydrolysis. The result has been multiple generations of b-lactams with improved efficacy and tolerance to existing b-lactamases. However, pathogenic bacteria have in turn evolved further resistance mechanisms primarily by acquiring new or modified b-lactamases. This is typified by the emergence of extended spectrum b-lactamases that inactivate many of the latest generation cephalosporins and penicillins (but not carbapenems) 2 . Consequently, the past two decades have seen substantial increases in the utilization of carbapenems such as imipenem and meropenem. Predictably, this increase in carbapenem consumption has been accompanied by the emergence of carbapenem-resistant Gram-negative pathogens (CRGNP) 3, 4 . In particular, carbapenem-resistant Enterobacteriaceae (CRE) is a growing crisis across the globe 5 as witnessed by recent outbreaks in Chicago 6 and British Columbia 7 .
MBLs are an unmet clinical challenge
Carbapenemases, b-lactamases that inactivate carbapenems, can be divided into two categories based on their mechanism of b-lactam ring hydrolysis. The first use an active site serine residue that covalently attacks the b-lactam ring for example, KPC and OXA-48 types 8 . The second are MBLs that use Zn 21 atoms to activate a nucleophilic water molecule that opens the ring, for example, VIM and NDM types 9 . Several inhibitors of serine b-lactamases are clinically available as co-drugs in which the inhibitor is formulated with a b-lactam antibiotic in order to overcome resistance (for example, clavulanic acid with amoxicillin, tazobactam with piperacillin, sulbactam with ampicillin and the more recent serine b-lactamase inhibitor avibactam, which is in phase III clinical trials paired with various cephalosporins) 10 . Despite ongoing efforts 11,12, , there are no equivalent inhibitors for MBLs in the clinic for practical and technical reasons. First, until recently, MBL-derived CRE was not thought to be a major clinical problem and its rapid increase has outpaced MBLinhibitor development. Second, the development of a single inhibitor to neutralise key clinically important MBLs (VIM and NDM) has been deemed too technically challenging, and overcoming in vivo toxicity associated with cross reactivity with human metalloenzymes has been a concern. With the recent emergence of MBLs as a major clinical threat, a potent and safe inhibitor of MBLs particularly against VIM and NDM would greatly benefit infectious disease management.
Cell-based screen for inhibitors of NDM-1
We initiated a cell-based screen for inhibitors of the NDM-1 MBL using our in-house collection of dimethylsulphoxide (DMSO)-dissolved natural product extracts derived from environmental microorganisms. To increase the sensitivity of the screen to MBL inhibitor discovery we generated a test strain of Escherichia coli BW25113 in which the bamB and tolC genes were independently deleted (E. coli BW25113 DbamBDtolC). BamB is essential to outer membrane porin assembly and disruption results in increased permeability to small molecules 13 and TolC is a key component of tripartite small molecule efflux systems such as AcrA-AcrB-TolC that serve to actively eliminate small molecules from the cell 14 . Therefore, E. coli BW25113DbamBDtolC increases the sensitivity of the screen to discovery of hits. This strain was further modified by integrating the bla NDM-1 b-lactamase gene under control of the pLac promoter into the chromosome (E. coli BW25113 DbamBDtolCDaraDAB:: pLac(bla NDM-1 )). We screened this strain in the presence of a sub-lethal concentration of meropenem (one quarter of the minimum inhibitory concentration 0.125 mg ml 21 ) in combination with ,500 natural product extracts.
The screen generated one reproducible hit from an extract of a strain of Aspergillus versicolor (as identified by 18S rRNA gene sequence) with excellent ability to restore meropenem antibiotic activity against the E. coli screening strain. The selectivity of the extract to neutralise NDM-1 activity in vitro was confirmed using purified enzyme and the colorimetric b-lactamase substrate nitrocefin and with the carbapenem drug meropenem. Activity-guided purification of the active compound from the fermentation broth of A. versicolor and subsequent detailed chemical characterization identified the MBL inhibitor as aspergillomarasmine A (AMA; Fig. 1a , Extended Data Table 1 and Extended Data Figs 1-5), a fungus-derived molecule that was discovered and reported in the early 1960s for its wilting and necrotic activity on plant leaves 15 . This molecule was re-evaluated in the 1980s as an inhibitor of angiotensin-converting enzyme (ACE) 16 and in the early 1990s as a preclinical candidate for the inhibition of activation of human endothelin 17 , a peptide that modulates blood vessel muscle contraction. The activation of this vasoconstricting peptide requires endothelin-converting enzyme, which, like angiotensin-converting enzyme, is a metalloproteinase that shares some mechanistic similarities with MBLs. This previous work demonstrated that AMA was well-tolerated and had low toxicity in mice (dose lethal to 50% of animals tested (LD 50 ) was 159.8 mg per kg, i.v. compared to EDTA at 28.5 mg per kg) and had no effect on mean atrial blood pressure 18 .
AMA is a potent inactivator of MBLs
AMA showed potent in vitro dose-dependent inhibition of NDM-1 and the related MBL VIM-2 ( Fig. 1b) , with weaker activity against the IMP-7 MBL. AMA had no effect on the serine b-lactamases TEM-1 and CTX-M-15 as well as the serine carbapenemases KPC-2 and OXA-48 ( Fig. 1b and Extended Data Fig. 6b ). The fact that AMA was identified as an inhibitor of unrelated mammalian metalloproteinases in the past suggested that the compound interacts with the MBL metal centres. Inhibition of NDM-1 was shown to be irreversible after removal of AMA by gel filtration (Fig. 1c ), but enzymatic activity could be restored by addition of excess ZnSO 4 , consistent with a metal depletion mechanism (Fig. 1d ). The inhibition of mammalian metalloenyzmes could be seen as a potential side effect, however, AMA was only able to reduce the activity of rabbit lung ACE by , 35% in concentration-response assays (Extended Data Fig. 6a ). Extended incubation of the metalloenzymes NDM-1, VIM-2, IMP-7 and ACE at high concentrations of AMA (0.5 mM) in Zn 21 -depleted buffer prepared as previously described 19 led to complete inactivation of NDM-1 and VIM-2, and ,70% and ,50% inhibition of activity in IMP-7 and ACE, respectively, demonstrating selectivity towards NDM and VIM MBLs (Extended Data Table 2 ). Time-dependent inactivation was shown to be saturable for NDM-1 (K i 5 11 nM, k 12 5 0.0062 s 21 ) and VIM-2 (K i 5 7 nM, k 12 5 0.0065 s 21 ) ( Fig. 1e ), consistent with an inactivation mechanism whereby AMA removes Zn 21 ions similar to known in vitro chelators that interact with subclass B1 MBLs 20 . This mechanism of action was confirmed by inductively coupled mass spectrometry that showed a loss of , 1.8 Zn equivalents in NDM-1 inactivated by AMA (Fig. 1f ).
Systematic titration of AMA and meropenem concentrations against our engineered E. coli and a panel of clinical CRE strains demonstrated that AMA restored meropenem activity consistent with NDM inhibition. Checkerboard MIC studies confirmed the expected synergy between meropenem and AMA only in NDM-1-expressing CRE and not in carbapenem-sensitive strains (Fig. 2a, b ). Fractional inhibitory concentration (FIC) index values were determined to be , 0.1 for a panel of 16 clinical CRE isolates tested against meropenem and AMA combinations (FIC values of # 0.5 are defined as synergistic 21 ) (Extended Data Table 3 ). Potentiation of AMA (8 mg ml 21 ) with meropenem was further investigated using 229 MBL positive (SPM-1, IMP, NDM, AIM and VIM) non-clonal clinical isolates (Enterobacteriaceae, Acinetobacter spp. and Pseudomonas spp.) (Fig. 2c) . A total of 76 isolates were also tested that possessed serine carbapenemases, or MBLs and serine carbapenemases. Strains were amassed over a 10 year period as part of a global MBL collection including isolates from Russia, India, Pakistan, Australia, North Africa and South America. AMA restored meropenem sensitivity (2 mg ml 21 ) in 88% of NDM positives isolates and 90% of VIM positive isolates. Importantly, AMA was active in Pseudomonas spp. (mainly Pseudomonas aeruginosa), which are viewed as a highly challenging model for new antibiotics. AMA showed very little potentiation with SPM-1, IMP and AIM but these MBLs are less numerous than the global VIM and NDM MBLs and therefore deemed to be less clinically relevant. The lack of potentiation with IMP-expressing strains correlates well with biochemical data showing less potent inactivation of purified IMP-7 compared to NDM-1 or VIM-2 (Extended Data Table 2 ).
AMA reverses carbapenem resistance in vivo
The resistance profile of NDM-1-positive clinical CRE and the efficacy with which AMA potentiated meropenem activity against NDM-1positive clinical CRE suggested that AMA would reverse NDM-1mediated resistance to meropenem in vivo and restore clinical efficacy of this antibiotic. To test this, CD1 mice were infected intraperitoneally with a lethal dose of NDM-1-positive K. pneumoniae N11-2218 
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to initiate a lethal systemic infection and the effects of meropenem or AMA monotherapy or antibiotic-inhibitor combination therapy was evaluated. Preliminary dosing experiments determined empirically that the bacterial load of NDM-1-positive K. pneumoniae in tissues was unaffected by treatment with AMA alone, and that this strain was resistant to meropenem monotherapy at doses below 50 mg per kg, leading to lethal infection (Extended Data Fig. 7 ). However, combination therapy with AMA and meropenem significantly reduced the bacterial load in the spleen (Fig. 3a) and to a lesser extent in the liver (Fig. 3b ) after a single intraperitoneal dose. Remarkably, although meropenem or AMA alone were unable to prevent lethal infection by NDM-1-positive K. pneumoniae, a single dose of combination therapy led to . 95% survival at 5 days following infection (Fig. 3c ). AMA presents a non-toxic candidate for an antibiotic adjuvant that can overcome resistance mediated by NDM and VIM MBLs and resensitize carbapenem-resistant Gram-negative pathogens to carbapenems. Active drug/inhibitor combinations continue to be highly successful in the clinic with inhibitors targeted to serine b-lactamases 22 . AMA presents for the first time, in vitro and in vivo, complementary activity against key MBLs that have become rapidly global and result in significant human morbidity particularly in developing countries. In combination with a b-lactam antibiotic such as meropenem as we show here, resistance can be overcome and antibiotic activity fully restored. AMA (or semi-synthetic derivatives) is therefore an excellent lead for an antibiotic adjuvant co-therapy to address the recent emergence of MBLs in the clinic.
METHODS SUMMARY
E. coli strain BW25113 was modified by deletion of the bamB and tolC genes so as to increase permeability to and reduce efflux of small molecules. This strain was then further modified by the single-copy chromosomal insertion of the bla NDM-1 gene under control of the pLac promoter. Microbial natural product extracts were screened against this strain in the presence of sublethal one-quarter MIC meropenem. AMA was purified from a hit extract and its structure elucidated by NMR, mass spectrometry and polarimetry. Half-maximum inhibitory concentration (IC 50 ) values for AMA were determined using nitrocefin (for MBLs and Ser BLs) and furanacryloyl-L-phenylalanylglycylglycine (for ACE) 23 as reporter substrates against the following purified enzymes: MBLs IMP-7, VIM-2, and NDM-1; SBLs CTX-M-15, KPC-2, OXA-48 and TEM-1; as well as ACE from rabbit lung. IC 50 , reversibility, Zn 21 restoration, and inactivation enzyme assays were performed in 50 mM HEPES pH 7.5 and measured using a SpectraMax reader (Molecular Devices). ICP-MS experiments were conducted using purified NDM-1 at 5 mg ml 21 and varying concentrations of AMA with subsequent dilution and transfer by nebulization into a NexION 3000 ICP mass spectrometer (Perkin Elmer). FIC values were determined using standard methods 21 Pseudomonas spp.
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Pseudomonas spp. 28 Synergistic properties of the two compounds were examined in a microtitre tray using BHI as the growth medium (Oxford Science Park, England) and an inoculum of 0.5 MacFarland. All plates contained the control strains Escherichia coli ATCC 25922 and Pseudomonas aeruginosa ATCC 27853. Overall, 226 nonclonal clinical isolates (Enterobacteriaceae, P. aeruginosa and Acinetobacter spp.) were challenged containing one of the following MBLs: SPM-1 (n 5 17), AIM-1 (n 5 8), NDM-1 (n 5 67), VIM-type (n 5 114) or IMP-type (n 5 20) . Three E. coli and 5 K. pneumoniae carrying VIM-1 also carried the serine carbapenemase KPC; and 4 E. coli and one K. pneumoniae carrying NDM-1 also possessed the carbapenemase OXA-181. Plates were incubated at 37 uC and read after 18 h. A subset of strains (48 in total) were randomly chosen and the method repeated to examine reproducibility and showed no deviation from the original data. Animal studies. All animals were housed in specific pathogen-free unit in the Central Animal Facility at McMaster University. All experimental protocols were approved by, and performed in accordance with the McMaster Animal Research Ethics Board. Female, 7-9-week-old CD1 mice were purchased from Charles River. Animals were randomized to cages of 5 per group for each experiment. Sample sizes were chosen based on empirical data from pilot experiments and to maximize statistical power. The preparation of treatments, animal infections, and tissue processing was performed by two independent investigators to maximize blinding. Bacterial infections. Experiments were based on previously established murine models of infection with b-lactamase-expressing Enterobacteriaceae 29, 30 . Mice were infected intraperitoneally (i.p.) with a dose of 2 3 10 6 colony-forming units (c.f.u.) of Klebsiella pneumoniae N11-2218 for all organ bacterial load experiments, or with a dose of 5 3 10 7 c.f.u. for all survival experiments. For all organ bacterial load experiments, mice were euthanized 48 h post-infection, and spleen and liver were collected. Organs were placed into 1 ml sterile PBS on ice, and then homogenized (Mixer Mill 400; Retsch). Organ homogenates were then serially diluted in PBS, and plated on Brilliant Green agar (Oxoid) for c.f.u. enumeration. For survival curves, mice were monitored for endpoint until day 4 post-infection.
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For all experiments, mice were treated 30 min post-infection with a specified subcutaneous dose of either PBS, meropenem, AMA inhibitor, or a combination of both antibiotic and inhibitor.
